Dr. Van Tine is the Sarcoma Program Director, Director of the Phase 1 Program at Alvin J. Siteman Cancer Center and Co-Director of the Adolescence and Young Adult Program at the Alvin J. Siteman Cancer Center. He came to Washington University in St. Louis/Barnes Jewish Hospital where he did his Internal Medicine Residency and Medical Oncology Fellowship after completing his M.D. and Ph.D. degrees at the University of Alabama at Birmingham in 2005. He then joined the laboratories of James J.D. Hsieh, M.D., Ph.D. and then Matthew Ellis, M.B., B.Chir., Ph.D., where he pursued his postdoctoral fellowship studying mouse genetics and genomics while clinically specializing in the treatment of sarcoma. His translational laboratory identified a common metabolic defect in sarcoma, the loss of ASS1 expression. His lab is currently working toward translating this finding and many others into the clinic via clinical trials.
Alliance for Rare Cancers I Jedi Rare Cancer Foundation
P.O. Box 683501, Park City, Utah 84068
The Alliance for Rare Cancers is a fiscally sponsored program of the Jedi Rare Cancer Foundation, a 501(c)(3) nonprofit organization, accepting tax-deductible donations from individuals, corporations, family-advised funds, and foundations. Federal Tax ID 86-2610819. All donations are tax deductible as allowed by law.
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.